Conditions: Hypercholesterolemia
Keywords: lipid-lowering drugs statin intolerance
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 56
Healthy volunteers: no

Brief summary:
This study will assess the Low-Density Lipoprotein-Cholesterol (LDL-C) lowering efficacy and safety of ETC-1002 versus placebo in participants with hypercholesterolemia and a history of statin intolerance.

Detailed description:

Arms:
arm 1: ETC-1002 treatment, once daily oral arm 2: Placebo treatment, once daily oral

Interventions: intervention 1: ETC-1002 intervention 2: Placebo
Intervention descriptions: intervention 1: Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day intervention 2: Placebo once daily for 8 weeks

Protocol document: